Acarix has initiated a new partnership with two new distributors; Bodenwinkler in Switzerland and Neucomed in Austria 

As an important part of our continued work in creating a better market access for the CADScor (R) System in our key markets, we are happy to announce the following new partnership and Distributors; Neucomed in Austria and Bodenwinkler in Switzerland. This to further build and strengthen presence and awareness of the CADScor®System in these two markets.

Please take the opportunity to learn more about our new partners>>

http://www.bodenwinkler.ch/

http://www.neucomed.com/

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.